Multiple myeloma dating service gpupdate not updating policy
Patients received a median of 2 (range 1-4) prior lines of therapy; 60% were lenalidomide refractory.
The most common grade 3/4 treatment-emergent adverse events were thrombocytopenia (31%), lymphopenia (24%), anemia (21%), and neutropenia (21%).
Other drugs for multiple myeloma include Celgene’s Thalomid, Johnson and Johnson’s (JNJ) Doxil and Darzalex, and Novartis’s (NVS) Farydak.
CELG) has been working on its immunomodulatory backbone drugs Revlimid and Pomalyst to develop combination therapies that can be used for treating all lines of MM (multiple myeloma).
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment options and poor survival outcomes.
The increasing adoption of lenalidomide-based therapy for frontline treatment of MM has resulted in a need for effective regimens for lenalidomide-refractory patients.
According to the National Cancer Institute, “Adult acute myeloid leukemia [AML] is a cancer of the blood and bone marrow.Of these, 10 patients received the first daratumumab dose as a single infusion (16 mg/kg Day 1 Cycle 1) and 75 patients received a split first dose (8 mg/kg Days 1-2 Cycle 1).Subsequent dosing was per the approved schedule for daratumumab.Celgene’s strategy involves combining its knowledge and infrastructure in hematology, oncology, and inflammation with those of other prominent healthcare players.The launch of Johnson & Johnson’s Darzalex (daratumumab) has boosted the sales of Celgene’s Pomalyst.
Therapies are also being developed for both aggressive and standard disease progression patients.